

03-25-03

PTA 6067 (3030/US)  
PATENT

1617



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Gary S. Jacob et al.

Art Unit 157

Serial No. 09/023,401

Filed February 12, 1998

Confirmation No. 6896

For USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCIAL

COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS

VIRUS INFECTIONS

Examiner R. Travers

TECH CENTER 9600/2900

MAR 27 2003

RECEIVED

March 24, 2003

TO THE COMMISSIONER FOR PATENTS,

SIR:

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicant submit copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

I certify that the item contained in this statement was first cited in a communication from the United States Patent Office in a counterpart U.S. application (serial No. 09/355,446, Att. Ref. No. PHA 6180) not more than three months prior to the filing of this statement.

Respectfully submitted,

*Patricia K. Fitzsimmons*

Patricia K. Fitzsimmons, Reg. No. 52,894  
SENNIGER, POWERS, LEAVITT & ROEDEL  
One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102  
(314) 231-5400

PKF/rle

Express Mail Label No. EV 233499037 US